IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants.
IBT is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Bryggargatan 10, 11121 Stockholm – Sweden
|Date||Trading entity / Person||Association||Trade type||Volume|
|09.06.23||Maria Ekdahl||Other||Buy||SEK 49,956.00|
|23.05.23||Anders Kronström||Other||Buy||SEK 56,482.50|
|23.05.23||Anthon Jahreskog||Other||Buy||SEK 36,593.00|
|23.05.23||Maria Ekdahl||Other||Buy||SEK 19,995.00|
|23.05.23||Anthon Jahreskog||Other||Buy||SEK 6,377.20|
|23.05.23||Anthon Jahreskog||Other||Buy||SEK 6,269.92|
|22.05.23||Maria Ekdahl||Other||Buy||SEK 30,487.00|
|20.05.23||Anders Kronström||Other||Buy||SEK 82,250.00|
|21.11.22||Maria Ekdahl||Other||Buy||SEK 15,800.00|
|30.05.22||Staffan Strömberg||Other||Buy||SEK 840,000.00|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.